Abbott Laboratories
Abbott Park, IL 60064
Abbott's HUMIRA-® (adalimumab) Receives FDA Approval for Inhibiting Structural Joint Damage and Improving Physical Function in Patients with Psoriatic Arthritis
Study Results Showed HUMIRA Inhibited the Progression of Structural Joint Damage in 86 Percent of Psoriatic Arthritis Patients at 48 Weeks ABBOTT PARK, Ill., Nov. 14 // -- Abbott announced today that the U.S. Food and Drug Administration (FDA) approved an expanded indication for HUMIRA(R) (adalimumab) that includes inhibiting structural joint damage and improving physical function in patients...
Read More »Abbott Begins Early International Launch of XIENCE(TM) V Everolimus Eluting Coronary Stent System
Company Expects to Achieve a Leadership Position in Drug-Eluting Stent Market with XIENCE V ABBOTT PARK, Ill., Oct. 3 / - Abbott (NYSE:ABT) today announced that it has begun the international launch of the XIENCE(TM) V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease earlier than the company's original projections. The XIENCE V stent system will be launched in...
Read More »Abbott Announces European Launch of Next-Generation Device Designed to Treat Patients at Risk of Stroke
Filter-Based Embolic Protection System Provides Advanced Treatment for Patients Undergoing a Carotid Stenting Procedure ABBOTT PARK, Ill., Sept. 13 -- Abbott (NYSE:ABT) announced today CE Mark approval and European launch of the company's next- generation embolic protection device, the Emboshield(R) PRO Embolic Protection System. Embolic protection devices are designed to capture and remove...
Read More »Abbott Reminds U.S. FreeStyle-® and FreeStyle Flash-® Blood Glucose Meter Users to Verify Units of Measure when they Test
Update to Prior Notification - ALAMEDA, Calif., July 20 / -- Abbott (NYSE:ABT) is reminding users of its FreeStyleÃ-® and FreeStyle FlashÃ-® blood glucose meters in the United States to check to make sure their meter is displaying the correct unit of measure (milligrams per deciliter, mg/dL) and strip calibration code each time they test. Abbott previously communicated that in some cases,...
Read More »Abbott to Preview m2000(TM) Real-Time PCR Diagnostics System Designed to Provide Fast, Efficient Testing in the Molecular Lab
U.S. Premarket Approval Application Submitted for HIV-1 Viral Load Test for Use on the Automated System - DES PLAINES, Ill., July 21 -- Abbott Molecular will preview its new automated molecular diagnostics system, the m2000(TM), at the annual meeting of the American Association for Clinical Chemistry (AACC) in Chicago (July 23-27). The m2000 is based on real-time polymerase chain reaction (PCR)...
Read More »Catheter accesses hard-to-reach areas.
Consisting of several hair-thin, stainless steel strands braided together, Asahi TornusÃ-® delivers therapeutic, minimally invasive balloon catheters and stents to coronary arteries and other vessels blocked with chronic occlusions. Safety-release valve at proximal end indicates when device has reached maximum rotation, and tapered distal tip with radio-opaque marker provides optimal...
Read More »Carotid Stent treats patients at risk of stroke.
XactÃ-® Carotid Stent treats diseased cartoid arteries in neck that have become clogged or partially blocked due to build-up of fatty plaque and debris. Self-expanding, closed-cell design creates tightly knit yet highly flexible mesh to help restore inner diameter of cartoid artery and promote smooth inner vessel surface. Stent is used in combination with fully retractable Emboshield filter,...
Read More »Abbott Completes Acquisition of Tendyne Holdings, Inc.
ABBOTT PARK, Ill. - Abbott (NYSE: ABT) announced today that it has completed its acquisition of Tendyne Holdings, Inc., a private medical device company focused on developing minimally invasive mitral valve replacement therapies. Abbott acquired the equity of Tendyne that it did not already own for $225 million upfront, resulting in a total transaction value of $250 million, plus potential future...
Read More »Abbott to Broaden Foundation in Structural Heart Therapies with Two Mitral Valve Transactions
• Acquisition of Tendyne Holdings, Inc. to Expand Abbott's Mitral Valve Therapies • In Separate Transaction, Abbott Has Provided Capital and Secured an Option to Purchase Cephea Valve Technologies ABBOTT PARK, Ill. - Abbott (NYSE: ABT) announced today that it has entered into an agreement to purchase Tendyne Holdings, Inc., a private medical device company focused on developing minimally...
Read More »Abbott to Present at RBC Capital Markets' Healthcare Conference
ABBOTT PARK, Ill., Feb. 15, 2011 -- Abbott (NYSE: ABT) will present at the 2011 RBC Capital Markets' Healthcare Conference on Thursday, March 3, 2011. Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a presentation on the company at 10 a.m. Central time. A live audio webcast of the presentation will be accessible through Abbott's Investor Relations Web...
Read More »Abbott Acquisition of Advanced Medical Optics Clears U.S. Antitrust Review
ABBOTT PARK, Ill., Feb. 6 -- Abbott (NYSE:ABT) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) applicable to Abbott's cash tender offer to purchase all of the outstanding shares of common stock of Advanced Medical Optics (AMO) expired last night at 11:59 p.m. Eastern time. The expiration of the HSR waiting period satisfies one of the...
Read More »Abbott Expands Its Growing Medical Device Business with Acquisition of Advanced Medical Optics (AMO)
Adding an established global leader in ophthalmic care will provide long-term sustainable growth platform with more than $1 billion in annual sales Acquisition gives Abbott a leadership position in another large and growing medical device segment Abbott expects this transaction to be neutral to ongoing earnings per share in 2009 and accretive beginning in 2010 ABBOTT PARK, Ill. and SANTA ANA,...
Read More »Abbott to Present at Cowen and Company Health Care Conference
ABBOTT PARK, Ill., March 7 -- Abbott (NYSE:ABT) will present at the Cowen and Company 28th Annual Health Care Conference on Monday, March 17, 2008. Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a formal presentation on the company at 10:30 a.m. Central time. A live audio webcast of the presentation will be accessible through Abbott's Investor...
Read More »Abbott to Present at Lehman Brothers Healthcare Conference
ABBOTT PARK, Ill., March 7 -- Abbott (NYSE:ABT) will present at the Lehman Brothers Eleventh Annual Global Healthcare Conference on Tuesday, March 18, 2008. Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a formal presentation on the company at 8:30 a.m. Central time. A live audio webcast of the presentation will be accessible through Abbott's Investor...
Read More »Abbott to Present at Merrill Lynch Healthcare Conference
ABBOTT PARK, Ill., Jan. 29 / -- Abbott will present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on Tuesday, Feb. 5, 2008. Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a formal presentation on the company at 9:20 a.m. Central time. A live audio webcast of the presentation will be accessible through Abbott's...
Read More »Abbott to Present at JP Morgan Healthcare Conference
ABBOTT PARK, Ill., Dec. 21 -- Abbott (NYSE:ABT) will present at the 26th Annual JP Morgan Healthcare Conference on Monday, Jan. 7, 2008. Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a formal presentation on the company at 11:00 a.m. Central time. A live audio webcast of the presentation will be accessible through Abbott's Investor Relations Web site...
Read More »Abbott and Caprion Extend Partnership to Discover Antibody Targets for Cancer
ABBOTT PARK, Ill. and MONTREAL, June 6 -- Abbott (NYSE:ABT) and Caprion Proteomics, a general partnership wholly owned by Thallion Pharmaceuticals have extended their discovery partnership to investigate viable human therapeutic antibody targets for oncology using their CellCartaÃ-® technology platform. The two companies began working together on lung cancer targets three years ago. The...
Read More »